Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
38
-
Total 13F shares, excl. options
-
7.73M
-
Shares change
-
+7.73M
-
Total reported value, excl. options
-
$204M
-
Value change
-
+$204M
-
Number of buys
-
38
-
Price
-
$26.56
Significant Holders of Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) as of Q3 2018
38 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q3 2018.
Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) has 38 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.73M shares
of 45.1M outstanding shares and own 17.15% of the company stock.
Largest 10 shareholders include Sofinnova Ventures Inc (2.1M shares), SCOPIA CAPITAL MANAGEMENT LP (1.59M shares), FMR LLC (1.23M shares), PRICE T ROWE ASSOCIATES INC /MD/ (389K shares), ALLIANCEBERNSTEIN L.P. (325K shares), MILLENNIUM MANAGEMENT LLC (320K shares), GOLDMAN SACHS GROUP INC (311K shares), venBio Select Advisor LLC (310K shares), Cormorant Asset Management, LP (200K shares), and BAKER BROS. ADVISORS LP (150K shares).
This table shows the top 38 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.